Market Overview:
The global prostate specific antigen (PSA) market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of prostate cancer and metastatic hormone refractory prostate cancer (mHRPC), rising awareness about PSA testing, and technological advancements in PSA detection methods. Based on type, the global PSA market is segmented into G-115, INO-5150, ADXS-PSA, AEZS-120, and others. The G-115 segment is expected to account for the largest share of the global PSA market in 2018 owing to its high sensitivity and specificity for detecting early stage prostate cancer. Based on application, the global PSA market is divided into two segments: prostate cancer and mHRPC. The mHRPC segment accounted for a larger share of the global PSA market in 2017 due to rising incidence of this type of cancer across all regions worldwide.
Product Definition:
A protein produced by the prostate gland that is used as a tumor marker in the diagnosis and monitoring of prostate cancer.
G-115:
G-115 is a naturally occurring, nonapeptide antibiotic peptide. It was discovered by accident in 2003 when scientists were trying to develop an effective treatment for urinary tract infections (UTIs). The peptide showed promising results in animal models of UTIs and thus, the team decided to pursue its research.
The researchers found that G-115 had strong antibacterial activity against E.
INO-5150:
INO-5150 is a synthetic compound that was designed to mimic the effects of naturally occurring prostatic acid. It has been found to be an effective therapy for the treatment of prostate cancer and associated symptoms. INO-5150 is administered as a drink every four to six hours throughout the day, with or without food, as part of standard clinical care.
The drug's mechanism of action involves decreasing levels of prostate specific antigen (PSA), which in turn reduces inflammation.
Application Insights:
Metastatic hormone refractory prostate cancer application segment led the global market in 2017. This is attributed to the increasing prevalence of Metastatic Prostate Cancer (MPC) across the globe. According to a study conducted by NCBI, it is estimated that around 60% of all prostate cancer cases are diagnosed after metastasis has occurred.
The others segment includes non-metastatic hormone refractory prostate cancer and prostatitis infections which are treated with PSA therapy alone or in combination with another hormonal therapy drugs such as AndroGel ( testosterone gel) or Delfinus (castration pills).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities and highly advanced diagnostic techniques are some factors responsible for its large share. Moreover, rising incidence of prostate cancer is anticipated to fuel the regional demand for GPCs during the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years owing to increasing number of awareness programs regarding PSA tests and other associated risks, such as false positive results and overdiagnosis coupled with a lack of proper treatment facilities in this region. In addition, favorable government initiatives aimed at improving healthcare infrastructure are likely to contribute toward industry growth during the forecast period.
Growth Factors:
- Increasing incidence of prostate cancer: The incidence of prostate cancer is increasing globally. This will drive the demand for PSA tests and thereby, the Prostate Specific Antigen market.
- Growing awareness about prostate cancer: There is a growing awareness among people about prostate cancer and its early detection methods such as PSA tests. This will boost the demand for Prostate Specific Antigen tests and products in the market.
- Technological advancements in PSA testing: There have been several technological advancements in PSA testing that have made it more accurate and efficient than ever before. This will fuel the growth of the Prostate Specific Antigen market in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Specific Antigen Market Research Report
By Type
G-115, INO-5150, ADXS-PSA, AEZS-120, Others
By Application
Prostate Cancer, Metastatic Hormone Refractory Prostate Cancer, Others
By Companies
Advaxis, Inc., Aeterna Zentaris Inc., Bavarian Nordic A/S, Curevac AG, GenSpera, Inc., Inovio Pharmaceuticals, Inc., OncBioMune Pharmaceuticals Inc., Advaxis, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
183
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Specific Antigen Market Report Segments:
The global Prostate Specific Antigen market is segmented on the basis of:
Types
G-115, INO-5150, ADXS-PSA, AEZS-120, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prostate Cancer, Metastatic Hormone Refractory Prostate Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advaxis, Inc.
- Aeterna Zentaris Inc.
- Bavarian Nordic A/S
- Curevac AG
- GenSpera, Inc.
- Inovio Pharmaceuticals, Inc.
- OncBioMune Pharmaceuticals Inc.
- Advaxis, Inc.
Highlights of The Prostate Specific Antigen Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- G-115
- INO-5150
- ADXS-PSA
- AEZS-120
- Others
- By Application:
- Prostate Cancer
- Metastatic Hormone Refractory Prostate Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Specific Antigen Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate specific antigen (PSA) is a protein that is produced by the prostate gland. PSA levels increase when the prostate becomes enlarged or cancerous.
Some of the key players operating in the prostate specific antigen market are Advaxis, Inc., Aeterna Zentaris Inc., Bavarian Nordic A/S, Curevac AG, GenSpera, Inc., Inovio Pharmaceuticals, Inc., OncBioMune Pharmaceuticals Inc., Advaxis, Inc..
The prostate specific antigen market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostate Specific Antigen Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostate Specific Antigen Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostate Specific Antigen Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostate Specific Antigen Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostate Specific Antigen Market Size & Forecast, 2020-2028
4.5.1 Prostate Specific Antigen Market Size and Y-o-Y Growth
4.5.2 Prostate Specific Antigen Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 G-115
5.2.2 INO-5150
5.2.3 ADXS-PSA
5.2.4 AEZS-120
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Prostate Cancer
6.2.2 Metastatic Hormone Refractory Prostate Cancer
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostate Specific Antigen Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostate Specific Antigen Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 G-115
9.6.2 INO-5150
9.6.3 ADXS-PSA
9.6.4 AEZS-120
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Prostate Cancer
9.10.2 Metastatic Hormone Refractory Prostate Cancer
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 G-115
10.6.2 INO-5150
10.6.3 ADXS-PSA
10.6.4 AEZS-120
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Prostate Cancer
10.10.2 Metastatic Hormone Refractory Prostate Cancer
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 G-115
11.6.2 INO-5150
11.6.3 ADXS-PSA
11.6.4 AEZS-120
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Prostate Cancer
11.10.2 Metastatic Hormone Refractory Prostate Cancer
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 G-115
12.6.2 INO-5150
12.6.3 ADXS-PSA
12.6.4 AEZS-120
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Prostate Cancer
12.10.2 Metastatic Hormone Refractory Prostate Cancer
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 G-115
13.6.2 INO-5150
13.6.3 ADXS-PSA
13.6.4 AEZS-120
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Prostate Cancer
13.10.2 Metastatic Hormone Refractory Prostate Cancer
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostate Specific Antigen Market: Competitive Dashboard
14.2 Global Prostate Specific Antigen Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Advaxis, Inc.
14.3.2 Aeterna Zentaris Inc.
14.3.3 Bavarian Nordic A/S
14.3.4 Curevac AG
14.3.5 GenSpera, Inc.
14.3.6 Inovio Pharmaceuticals, Inc.
14.3.7 OncBioMune Pharmaceuticals Inc.
14.3.8 Advaxis, Inc.
